• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
[Retracted] MicroRNA‑337 inhibits colorectal cancer progression by directly targeting KRAS and suppressing the AKT and ERK pathways.[已撤回] 微小RNA-337通过直接靶向KRAS并抑制AKT和ERK通路来抑制结直肠癌进展。
Oncol Rep. 2022 Oct;48(4). doi: 10.3892/or.2022.8394. Epub 2022 Aug 31.
2
[Retracted] MicroRNA‑326 inhibits melanoma progression by targeting KRAS and suppressing the AKT and ERK signalling pathways.[已撤回] 微小RNA-326通过靶向KRAS并抑制AKT和ERK信号通路来抑制黑色素瘤进展。
Oncol Rep. 2023 Mar;49(3). doi: 10.3892/or.2023.8488. Epub 2023 Jan 27.
3
[Retracted] MicroRNA‑655 attenuates the malignant biological behaviours of retinoblastoma cells by directly targeting PAX6 and suppressing the ERK and p38 MAPK signalling pathways.[已撤回] 微小RNA-655通过直接靶向PAX6并抑制ERK和p38丝裂原活化蛋白激酶信号通路来减弱视网膜母细胞瘤细胞的恶性生物学行为。
Oncol Rep. 2022 Oct;48(4). doi: 10.3892/or.2022.8385. Epub 2022 Aug 10.
4
[Retracted] MicroRNA‑511 inhibits malignant behaviors of breast cancer by directly targeting SOX9 and regulating the PI3K/Akt pathway.[已撤回] 微小RNA-511通过直接靶向SOX9并调节PI3K/Akt通路来抑制乳腺癌的恶性行为。
Int J Oncol. 2022 Oct;61(4). doi: 10.3892/ijo.2022.5413. Epub 2022 Aug 31.
5
[Retracted] MicroRNA‑936 inhibits the malignant phenotype of retinoblastoma by directly targeting and deactivating the PI3K/AKT pathway.[已撤回]微小RNA-936通过直接靶向并失活PI3K/AKT通路来抑制视网膜母细胞瘤的恶性表型。
Oncol Rep. 2022 Oct;48(4). doi: 10.3892/or.2022.8389. Epub 2022 Aug 25.
6
[Retracted] MicroRNA‑628‑5p inhibits cell proliferation and induces apoptosis in colorectal cancer through downregulating CCND1 expression levels.[已撤回] 微小RNA-628-5p通过下调CCND1表达水平抑制结直肠癌细胞增殖并诱导其凋亡。
Mol Med Rep. 2023 Sep;28(3). doi: 10.3892/mmr.2023.13045. Epub 2023 Jul 7.
7
[Retracted] MicroRNA‑202 inhibits cell proliferation, migration and invasion of glioma by directly targeting metadherin.[已撤回] 微小RNA-202通过直接靶向黏附素抑制胶质瘤细胞的增殖、迁移和侵袭。
Oncol Rep. 2022 Jul;48(1). doi: 10.3892/or.2022.8344. Epub 2022 Jun 8.
8
[Retracted] MicroRNA‑760 inhibits cell proliferation and invasion of colorectal cancer by targeting the SP1‑mediated PTEN/AKT signalling pathway.[撤回]微小RNA-760通过靶向SP1介导的PTEN/AKT信号通路抑制结直肠癌的细胞增殖和侵袭。
Mol Med Rep. 2022 Aug;26(2). doi: 10.3892/mmr.2022.12783. Epub 2022 Jun 28.
9
[Retracted] MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway.[已撤回]微小RNA‑766通过直接靶向胰岛素受体底物2并调节PI3K/Akt通路来抑制甲状腺乳头状癌进展。
Int J Oncol. 2022 Jul;61(1). doi: 10.3892/ijo.2022.5376. Epub 2022 Jun 1.
10
[Retracted] miR‑802 inhibits the aggressive behaviors of non‑small cell lung cancer cells by directly targeting FGFR1.[已撤回] miR-802通过直接靶向FGFR1抑制非小细胞肺癌细胞的侵袭性行为。
Int J Oncol. 2022 Sep;61(3). doi: 10.3892/ijo.2022.5389. Epub 2022 Jul 7.

[已撤回] 微小RNA-337通过直接靶向KRAS并抑制AKT和ERK通路来抑制结直肠癌进展。

[Retracted] MicroRNA‑337 inhibits colorectal cancer progression by directly targeting KRAS and suppressing the AKT and ERK pathways.

作者信息

Liu Xuerong, Wang Yan, Zhao Jinglong

机构信息

Department of Oncology, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China.

Department of Hematology, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China.

出版信息

Oncol Rep. 2022 Oct;48(4). doi: 10.3892/or.2022.8394. Epub 2022 Aug 31.

DOI:10.3892/or.2022.8394
PMID:36043516
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9478972/
Abstract

Following the publication of this paper, it was drawn to the Editors' attention by a concerned reader that various panels showing data from flow cytometric experiments in Figs. 2D and 5D were strikingly similar to data appearing in different form in other articles by different authors. Owing to the fact that the contentious data in the above article were already under consideration for publication, or had already been published, elsewhere when it was submitted to , the Editor has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a reply. The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 38: 3187‑3196, 2017; DOI: 10.3892/or.2017.5997].

摘要

在本文发表后,一位关注此事的读者提醒编辑注意,图2D和5D中显示流式细胞术实验数据的各个面板与不同作者在其他文章中以不同形式出现的数据惊人地相似。由于上述文章中存在争议的数据在提交给[期刊名称]时已在其他地方被考虑发表或已发表,编辑决定从该期刊撤回本文。已要求作者对这些问题作出解释,但编辑部未收到答复。编辑就由此造成的不便向读者表示歉意。[《肿瘤学报告》38: 3187 - 3196,2017;DOI: 10.3892/or.2017.5997]